Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02062632CT.gov Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pleural Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Doxepin (this asset) | Mayo Clinic | P2 | C · 39 |
| Cyclophosphamide | Memorial Sloan Kettering Cancer Center | P1/2 | CCC |
| Pembrolizumab | Memorial Sloan Kettering Cancer Center | P1/2 | CCC |
| Icasp9M28Z T Cell Infusions | Memorial Sloan Kettering Cancer Center | P1/2 | CCC |
| Epigenetically Modified Autologous Tumor | National Cancer Institute (NCI) | P1 | CC |
| Allogenic Tumor Cell Vaccine (K562) | National Cancer Institute (NCI) | P1 | CC |
| Fapi-46 | Jonsson Comprehensive Cancer Center | P1 | CC |
| Celecoxib | National Cancer Institute (NCI) | P1 | CC |
| mt027 | Suzhou Maximum Bio-tech Co., Ltd. | P1 | NR |
Other indications for Doxepin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Anxiety Disorder | — | P3 | CC · 43 |
| Physiological Malfunction Arising From Mental Factor | — | P3 | CC · 43 |
| Dementia | — | P3 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CyclophosphamideMemorial Sloan Kettering Cancer CenterCCC
- PembrolizumabMemorial Sloan Kettering Cancer CenterCCC
- Icasp9M28Z T Cell InfusionsMemorial Sloan Kettering Cancer CenterCCC
- Epigenetically Modified Autologous TumorNational Cancer Institute (NCI)CC
- Allogenic Tumor Cell Vaccine (K562)National Cancer Institute (NCI)CC
Citation
Floatz Terminal. Doxepin in Pleural Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/doxepin-pleural-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →